Case Report
The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier
Table 1
Laboratory data on admission.
| | Complete blood count | | | White blood cell count | 12100/L | | Red blood cell count | 354 × 104/L | | Hemoglobin | 11.9 g/dL | | Hematocrit | 35.8% | | Platelets | 33.1 × 104/L | | Blood chemical | | | Aspartate aminotransferase | 23 IU/L | | Alanine aminotransferase | 12 IU/L | | Alkaline phosphatase | 117 IU/L | | Lactate dehydrogenase | 202 IU/L | | -GTP | 24 IU/L | | Total bilirubin | 0.7 mg/dL | | Creatine phosphokinase | 77 IU/L | | Total cholesterol | 312 mg/dL | | Triglyceride | 69 mg/dL | | Sodium | 136 mEq/L | | Chloride | 99 mEq/L | | Potassium | 4.5 mEq/L | | Uric acid | 4.2 mg/dL | | Blood urea nitrogen | 13 mg/dL | | Creatinine | 0.56 mg/dL | | Total protein | 6.7 g/dL | | Albumin | 4.6 g/dL | | C-reactive protein | 0.04 mg/dL | | Fasting plasma glucose | 79 mg/dL | | Hemoglobin A1c | 5.0% | | KL-6 | 151 U/mL | | Immunology | | | Immunoglobulin G | 782 mg/dL | | Immunoglobulin A | 145 mg/dL | | Immunoglobulin M | 48 mg/dL | | Complement titer (CH50) | 36.9 U/mL | | Complement C3 | 84 mg/dL | | Complement C4 | 18 mg/dL | | Antinuclear antibody | <40 | | HBs antigen | (+) | | HBe antigen | (−) | | HBe antibody | (+) | | HBV-DNA | 3.4 log (10) IU | | HCV-antibody | (−) | | Coagulation | | | APTT | 25.1 second | | PT-INR | 0.80 | | <ELISA> | | | MPO-ANCA | 93 EU | | PR3-ANCA | <10 EU | | Urinalysis | | | pH | 7.0 | | Specific gravity | 1.010 | | Glucose | (−) | | Protein | (−) | | Cast | Hyaline cast (+) | | Erythrocytes | 1–5/HPF | | Leukocytes | 1–5/HPF |
|
|
γ-GTP: gamma-glutamyl transpeptidase, PR3-ANCA: proteinase-3 anti-neutrophil cytoplasmic antibody, MPO-ANCA: myeloperoxidase anti-neutrophil cytoplasmic antibody, APTT: activated partial thromboplastin time, PT-INR: prothrombin time-international normalized ratio.
|
